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Objective: To explore and quantify men’s preferences and willingness to pay (WTP) for 
attributes of medications for lower urinary tract symptoms associated with benign prostatic 
hyperplasia using a discrete choice experiment.
Subjects and methods: Men in the UK aged $45 years with moderate-to-severe lower urinary 
tract symptoms/benign prostatic hyperplasia (based on self-reported International Prostate 
Symptom Score $8) were recruited. An online discrete choice experiment survey was adminis-
tered. Eligible men were asked to consider different medication scenarios and select their preferred 
medication according to seven attributes: daytime and nighttime (nocturia) urinary frequency, 
urinary urgency, sexual and nonsexual side effects, number of tablets/day, and cost/month. 
A mixed-logit model was used to estimate preferences and WTP for medication attributes.
Results: In all, 247 men completed the survey. Men were willing to trade-off symptom improve-
ments and treatment side effects. Men preferred medications that reduced urinary urgency and 
reduced day- and nighttime urinary frequency. Men preferred medications without side effects 
(base-case level), but did not care about the number of tablets per day. WTP for symptomatic 
improvement was £25.33/month for reduced urgency (urge incontinence to mild urgency), and 
£6.65/month and £1.39/month for each unit reduction in night- and  daytime urination frequency, 
respectively. The sexual and nonsexual side effects reduced WTP by up to £30.07/month. There 
was significant heterogeneity in preferences for most attributes, except for reduced urinary 
urgency from urge incontinence to mild urgency and no fluid during ejaculation (dry orgasm).
Conclusion: To compensate for side effects, a medicine for lower urinary tract symptoms/
benign prostatic hyperplasia must provide a combination of benefits, such as reduced urgency 
of urination plus reduced nighttime and/or reduced daytime urination.
Keywords: benign prostatic hyperplasia, discrete choice experiment, erectile dysfunction, 
lower urinary tract symptoms, storage symptoms, urge incontinence
Introduction
Lower urinary tract symptoms (LUTS) are prevalent in aging men, with ~90% of men aged 
50 to 80 years suffering from potentially bothersome symptoms.1 Presenting symptoms 
include storage symptoms (ie, daytime urinary frequency, nocturia, urgency, urinary incon-
tinence), voiding symptoms (ie, slow stream, splitting or spraying, intermittency, hesitancy, 
straining, terminal dribble), and/or post-micturition symptoms (sensation of incomplete 
emptying, post-micturition dribble).1 All three symptoms are found in ~one-third of men 
with LUTS,2 but storage symptoms have been reported to be the most bothersome.1,3,4
The mechanisms leading to the development of LUTS are multifactorial.5 Benign 
prostatic hyperplasia (BPH) is reported to be a common cause of LUTS6,7 and 25% to 
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50% of men with BPH have LUTS.1,8 LUTS associated with 
BPH (LUTS/BPH) is reported to negatively affect quality of 
life, daily activities, and general health.9,10 LUTS/BPH has also 
been linked to sexual dysfunction (eg, erectile dysfunction)11,12 
and psychological dysfunction (eg, depression/anxiety)9,13 
in men.
Drug treatment is recommended for men with moderate-
to-severe LUTS, that is, those with an International Prostate 
Symptom Score (IPSS) $8, to provide symptomatic relief 
when conservative management strategies have been unsuc-
cessful or are not appropriate.1,5 Drug treatment options 
include α
1
-blockers, 5α-reductase inhibitors (5-ARIs), 
antimuscarinics, and phosphodiesterase type 5 inhibitors.1,5 
Combination therapy should be considered for men who have 
unresolved symptoms with monotherapy, for example, an 
α
1
-blocker plus an antimuscarinic or a 5-ARI.1,5
Patient preferences are an important consideration in the 
treatment of LUTS/BPH.5,14 Physicians should involve patients 
in the decision-making process to limit potential subsequent 
regret by the patient regarding some aspect(s) of the initiated 
treatment strategy,15 especially as patients’ and physicians’ 
preferences may not always be aligned.16 Discrete choice 
experiments (DCEs) are a common method to elicit patients’ 
preferences to understand what aspects of symptoms and treat-
ment are important to patients and the relative importance of 
these factors.17 Treatment choices require trade-offs between 
treatment benefits and side effects; DCEs are designed to 
capture and quantify these trade-offs. DCEs are being increas-
ingly used to assist with health care decision making during the 
regulatory process. Evaluation of patient preferences is recom-
mended by the US Food and Drug Administration18 and the 
German Institute for Quality and Efficiency in Health Care; the 
latter explicitly encourages the use of DCEs.19 The European 
Medicines Agency also advocates consideration of patients’ 
assessments of the risks and benefits of medications through the 
use of quantitative methods.20 DCEs have been used to assess 
men’s preferences for treatments for LUTS/BPH,21 BPH,22 
and overactive bladder.23 The previous study in LUTS/BPH 
used community dwelling men aged $40 years in the UK and, 
therefore, the present study is the first DCE that has focused 
specifically on men with symptoms of LUTS/BPH.
In the present study, a DCE was conducted in men with 
LUTS/BPH with the following objectives: 1) to explore 
men’s preferences for attributes of medications for LUTS/
BPH; 2) to estimate their willingness to pay (WTP), a mon-
etary measure of benefit for attributes of medications; 3) to 
determine the trade-offs they are prepared to make between 
the benefits and side effects of medication; and 4) to explore 
variations in preferences for attributes of medications.
Subjects and methods
DCEs are based on the assumption that medications are val-
ued by patients because of their characteristics or attributes.24 
In our DCE, medications (A, B, or no medicine) were 
described by a set of attributes (eg, symptom improvements, 
side effects, and cost) that differed in their attribute levels 
(eg, variations in extent of symptom improvement, pres-
ence or absence of side effects), thereby creating different 
scenarios associated with LUTS/BPH. Men were asked to 
hypothetically choose the medication they preferred in a 
series of such choice tasks. From these choices, preferences 
for medication were inferred, allowing the estimation of: 
relative importance of the attributes; trade-offs made between 
attributes; and WTP for attributes.
Attributes and levels
Following best practice recommendations,25 qualitative meth-
ods were used to select attributes and levels for the DCE. 
The LUTS/BPH medications in our study were described 
by seven attributes and corresponding levels (Table 1). 
These attributes and levels were identified from an earlier 
qualitative research phase of the study (ie, literature review 
Table 1 Attributes and levels in the Dce
Attribute Level
Daytime frequency of urinationa eight, ten, 12, or 14 times
nighttime frequency of urinationa One, two, three, or four times
Urgency of urination – when you 
need to urinate you usually…
have to rush to the toilet and 
leak before you get there (urge 
incontinence)b
cannot postpone and have to rush 
to the toilet in order not to wet 
yourself (severe urgency)
can postpone for a short while, 
without fear of wetting yourself 
(moderate urgency)
can postpone as long as necessary, 
without fear of wetting yourself 
(mild urgency)
sexual side effects no sexual side effectsb
No fluid during ejaculation 
(dry orgasm)
Decreased sexual desire
erectile dysfunction
nonsexual side effects no nonsexual side effectsb
Dry mouth
headaches
Dizziness
number of tablets One or two tablets per day
cost per monthc £5, £10, £20, or £40
Notes: aFrequency attributes enter the statistical analysis as deviation from the 
no-treatment alternative; bbase-case level; cincludes prescription fees, travel, and 
absenteeism from work. note that for urgency of urination, the extended text is 
what the men read in the survey, while the short labels in brackets are used in the 
paper for ease of reading.
Abbreviation: Dce, discrete choice experiment.
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and online discussion groups). Briefly, a structured literature 
review was conducted to find background information on 
LUTS/BPH and ensure that the subsequent study stages were 
based on existing evidence. Medline and Cochrane Database 
of Systematic Reviews were searched for articles in English 
that were published in 1991–2013. Combinations of the 
following search terms were used: “benign prostatic hyper-
plasia”, “prostatic hyperplasia”, “choice behavior”, “patient 
preference”, “decision making”, “patient participation”, and 
“attitude to health”. The search was augmented by searching 
the reference lists of the identified literature. The abstracts 
(where available) of all publications were read for relevance 
and the content of documents collected. A total of 362 unique 
papers were identified (after excluding 72 duplicates).
Five moderated asynchronous online discussion groups 
were used to collect qualitative data about men’s experiences 
of LUTS/BPH. Each discussion group lasted for 5 days and 
was hosted online on a secure and password protected bulletin 
board. Men residing in the UK with an IPSS score $8 were 
invited to take part in the discussion groups. The men (n=48) 
registered to a bulletin board with an anonymous username. 
Each day, a question about LUTS/BPH and its treatment was 
posed to and discussed by the men (day 1: LUTS/BPH and 
its effect on quality of life; day 2: management of symptoms; 
day 3: side effects of treatment; day 4: consultation with a 
doctor; and day 5: concluding comments). These questions 
were informed by the literature review. The discussions were 
downloaded and analyzed independently by three researchers 
using an inductive thematic analysis.26
The attributes and levels included in the DCE were those 
most relevant to men with LUTS/BPH and were identified in 
two separate researcher workshops based on findings from 
the literature review and the qualitative analysis. “Daytime 
frequency of urination” (or daytime urinary frequency) 
levels ranged from eight to 14 times based on evidence that 
the median urinary frequency was seven times in 24 hours 
(range 2 to 21) in asymptomatic men, with 95% voiding fewer 
than 12 times daily.27 The “nighttime frequency of urination” 
(nocturia) range was based on the IPSS instrument (range 
0 to 5) and a study that reported data from 24-hour voiding 
diaries (range 0 to 4).28 The levels of “urgency of urination” 
(urinary urgency) were adapted from the validated Patient 
Perception of Intensity of Urgency Scale.29,30 The attributes 
and levels for the sexual side effects (hypoactive sexual 
desire, as well as erectile and ejaculatory dysfunction) and 
nonsexual side effects (headaches, dizziness, and dry mouth), 
were based on the reported side effects of current LUTS/BPH 
medications, including α
1
-blockers, 5-ARIs, antimuscarinics, 
and phosphodiesterase type 5 inhibitors.1,5,31–34
Two of the attributes were not identified from the literature 
review and online discussion groups: number of daily tablets 
and cost of medication. Men may receive combination therapy 
for persistent LUTS/BPH, and therefore have preferences for 
the number of tablets to improve symptoms. The cost attribute 
was included to allow estimation of WTP for marginal changes 
in attribute levels. This attribute was framed as the total cost 
for men, including any prescription fees, travel expenses and 
absenteeism. The range of levels for the cost attribute was 
derived from earlier related studies21,35 and adjusted for infla-
tion using the consumer price index. This range was tested in 
the pilot study in two ways: by examining the proportion of 
men never selecting a treatment in the DCE choice sets and 
including a payment card contingent valuation instrument.
experimental design and survey structure
The attributes and levels resulted in 8,192 (46×21) different 
possible combinations of medication. To reduce this number 
for presentation to men in a survey, a D-efficient design was 
generated.36 In total, 30 choice sets (grouped into three sets of 
ten choice sets) were selected to reduce the burden of the survey 
for men. Each choice set included two different medicine 
options and a no medicine option (ie, continue with the baseline 
scenario described). Figure 1 presents an example choice set.
The questionnaire included four sections. Section 1: men 
were provided with information (text and pictures) about 
LUTS/BPH and then asked three multiple-choice questions 
to determine the level of bother from their urinary symptoms. 
These were measured on an 11-point scale (range, 0= not at 
all bothered to 10= very bothered; a “don’t know” option was 
also included). Men were also asked if they had ever visited a 
doctor about LUTS/BPH; were they currently taking medica-
tion to treat LUTS/BPH; and what treatments were received. 
Section 2: men considered a set of LUTS/BPH symptoms and 
were presented with questions about each of the seven attri-
butes, one by one, to familiarize themselves with the attributes 
used in the DCE. Section 3: the DCE choice sets followed by 
debriefing questions about how difficult/realistic they found 
the choice tasks and whether they considered all of the medi-
cation attributes when making their choices. Section 4: men 
were asked questions about their socioeconomic characteris-
tics and to complete the validated Beliefs about Medication 
Questionnaire.37 At the end of the survey, men were invited to 
provide any comments they had about the questionnaire.
Ethical approval for this study was granted by the College 
of Life Science and Medicine, University of Aberdeen, 
College Ethics Research Board (CERB), November 1, 
2013 – CERB/2013/8/942. The full survey is available from 
the corresponding author on request.
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Participants and recruitment
The DCE was a self-administered online survey and partici-
pation was voluntary; the DCE survey was conducted during 
March 19–26, 2014. The target population was 300 men living 
in the UK, recruited from the online panel of a market research 
company. Men invited to take part in the survey (identified from 
screening questions) were aged $45 years and had moderate-
to-severe LUTS/BPH, that is, self-reported IPSS $8. These 
inclusion criteria were selected based on a reported increased 
prevalence of storage symptoms in men aged $45 years1 and 
the IPSS categorization of LUTS as moderate or severe (scores 
of 8–19 or 20–35, respectively).1 The invited men received a 
detailed information sheet about the survey with a hyperlink. 
We assumed that by clicking on the hyperlink men consented 
to taking part in the study. Men were free to withdraw at any 
point without having to give any reason(s). Men received a 
reward if they completed the 15-minute survey (£1.50).
The DCE was pilot tested among a subgroup of 63 men 
to assess the clarity of wording used in the survey, as well 
as to check the appropriateness of the attributes and levels. 
The mean WTP for treatment using a payment card was £15, 
and more than a third of men always chose the no medicine 
option. Based on these responses, the range of the cost attri-
bute was lowered from £15, £30, £50, and £75 to £5, £10, 
£20, and £40 in the final DCE.
Data analysis
In the DCE, each man (i) was presented with a choice between 
three alternative actions (m), that is, taking medicine A, taking 
medicine B, or taking no medicine. Men were assumed to 
choose the alternative (ie, their most preferred option) that 
provided them with the highest utility (ie, overall benefit) in 
terms of symptom improvement, side effects, number of tablets, 
and cost (ie, the attributes included in the DCE). The utility 
(u
im
) that a man receives from an alternative is a function of the 
characteristics included in the DCE and an error term (ε
im
):
u
im
 = β
0
 
 + (β
1
 + σ
1i
) daytime frequency
im
 + (β
2
 + σ
2i
) nighttime frequency
im
 + (β
3
 + σ
3i
) mild urgency
im
 + (β
4
 + σ
4i
) moderate urgency
im
 + (β
5
 + σ
5i
) severe urgency
im
 +  (β
6
 + σ
6i
) no fluid during ejaculation sexual side 
effect
im
 + (β
7
 + σ
7i
) decreased desire sexual side effect
im
 + (β
8
 + σ
8i
) erectile dysfunction sexual side effect
im
 + (β
9
 + σ
9i
) dry mouth nonsexual side effect
im
 + (β
10
 + σ
10i
) headache nonsexual side effect
im
 + (β
11
 + σ
11i
) dizziness nonsexual side effect
im
 + (β
12
 + σ
12i
) number of tablets
im
 + β
13
 cost per month
im
 + ε
im
β
0
 is a constant term that denotes men’s general preference for 
medication versus no medication. Given dummy variables are 
used to analyze the categorical variables (later); the constant 
term also values these reference categories.
In the estimated model, each attribute can be associ-
ated with two coefficients, one representing the average 
utility of the attribute (β
1
 to β
13
), and another representing 
individual-specific preference variation for the attributes (σ
1i
 
to σ
12i
). These individual-specific preference variations allow 
Please imagine this situation:
• You have to urinate 14 times during the day. When you need to urinate you usually have to rush to the toilet and leak before you get 
there. During the night you wake up four times to go to the bathroom and urinate.
• You do not take any medicine to treat your symptoms. However, your general practioner has told you that there are medicines available 
that can improve the symptoms described above. These medicines, however, may have side effects.
Please compare the medicines and tick which, if any, you would take:
Description Medicine A Medicine B No medicine
Daytime frequency of urination Eight times 14 times 14 times
Nighttime frequency of urination Three times One time Four times
Urgency – when you need to urinate 
you usually…
Have to rush to the 
toilet and leak before 
you get there
Cannot postopone and have  
to rush to the toilet in order  
not to wet yourself
Have to rush to the toilet and leak 
before you get there
Sexual side effects of medicine No sexual side effects Decreased sexual desire You do not have any side effects
Nonsexual side effects of medicine Dry mouth Headaches You do not have any side effects
Number of tablets per day Two tablets One tablet You do not take any medicine
Cost per month £5 £20 £0
Please select your answer here:   
Figure 1 example Dce choice task.
Abbreviation: Dce, discrete choice experiment.
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that not all men will have the same preferences for medica-
tion and provide a measure of the variation in preferences in 
the population. σ
1i
 to σ
12i
 represents preference variation in 
the sample of men; if these coefficients are significant, this 
implies that preferences vary across the sample.
The interpretation of the average utility coefficient 
depends on the unit of measurement of the attribute. β
1
 and 
β
2
 represent the effect of a one-time reduction in day- and 
nighttime frequency of urination, respectively (and are mod-
eled as continuous variables). The urgency attribute, side 
effects attributes, and number of tablets attributes were coded 
as dummy variables. In this case, the coefficients representing 
the average utility are interpreted relative to the reference 
categories – these are “urinary incontinence” for the urinary 
urgency attribute, “none” for both the sexual and nonsexual 
side effects attributes, and one tablet per day for the number 
of tablets attribute. β
13
 indicates the effect of a £1 increase 
in the cost of treatment. The signs (+/-) of the coefficients, 
representing average utility, indicate whether a change in the 
attribute as described earlier has a positive or negative effect 
on medication utility. DCE responses were analyzed using a 
mixed-logit model;38 (Supplementary material).
From the mixed-logit results, we calculated WTP esti-
mates, which show the monetary amounts that men are 
willing to pay per month for a unit change in each of the 
significant attributes. This placed all attributes on a common 
and meaningful metric (money), which allows the relative 
importance of each attribute as well as strength of preference 
and the trade-offs men make between attributes to be com-
pared. WTP is calculated as the ratio of the average utility 
coefficient for the attribute and negative of the coefficient for 
the cost attribute. For example, (β
1
/-β
13
) is men’s WTP for 
one less daytime urination, while (β
8
/-β
13
) is men’s WTP to 
avoid the erectile dysfunction sexual side effect. Confidence 
intervals for WTP estimates were calculated using the Delta 
method.39 The WTP estimates were also used to assess the 
trade-offs that men were willing to make between symptom 
improvements and the side effects of medications.
Results
Men’s characteristics
A total of 5,212 individuals were invited to participate and 
1,097 opened the online survey (ie, clicked the hyperlink). 
Of those who opened the DCE, 450 individuals did not meet 
the eligibility criteria, 136 met the criteria but were excluded 
because the quota was full, and 201 only partially completed 
the survey. A total of 310 men completed the survey (63 men 
in the pilot sample and 247 in the final sample); responses 
from the final sample of 247 men were used for analysis.
The mean age of the sample was 62.32 years, 51.01% 
of men had their day-to-day activities limited because of 
a health problem or disability, and 46.15% of men were 
retired (Table 2). The reported mean IPSS of the population 
was 15.69 (standard deviation 5.99). In addition, men were 
generally bothered by urinary symptoms, more during the 
night (mean score 5.86) than the day (mean score 4.92) and 
by urinary urgency (mean score 5.73). Approximately half of 
the men had spoken to a doctor (45.34%) and less than a third 
received medication for their urinary symptoms (26.32%); 
a summary of prior medications is shown in Table 3.
estimation results
A total of 216 men (87.5%) stated that they considered all of 
the presented attributes. Across all of the choices in the DCE, 
Table 2 Baseline socioeconomic and disease characteristics
Characteristic Category Data
Age, n (sD) – 62.32 (9.05)
health, n
Day-to-day activities limited a lot 32 (12.96%)
limited a little 94 (38.06%)
no 121 (48.99%)
suffer from any 
chronic illness
Yes 142 (57.49%)
no 105 (42.51%)
Occupation,a n employed/self-employed 99 (40.08%)
Unemployed 21 (8.50%)
retired (receiving pension) 114 (46.15%)
looking after home or family 18 (7.29%)
long-term sick or disabled 22 (8.91%)
Other 14 (5.67%)
Annual income, n #£10,399 27 (10.93%)
£10,400–£20,799 53 (21.46%)
£20,800–£31,199 63 (25.51%)
£31,200–£51,999 72 (29.15%)
$£52,000
Prefer not to say
18 (7.29%)
14 (5.67%)
Bothered by urinary 
symptoms,b mean
Daytime frequency 4.92 (sD, 2.49)
nighttime frequency 5.86 (sD, 2.50)
Urgency 5.73 (sD, 2.56)
severity of urinary 
symptoms, n
Moderate (iPss 8–19) 182 (73.68%)
severe (iPss 20–35) 65 (26.32%)
iPss quality of life, n Delighted 4 (1.62%)
Pleased 8 (3.24%)
Mostly satisfied 40 (16.19%)
Mixed 102 (41.30%)
Mostly dissatisfied 52 (21.05%)
Unhappy 31 (12.55%)
Terrible 10 (4.05%)
spoken to doctor, n Yes 112 (45.34%)
no 134 (54.25%)
Do not know/could not say 1 (0.40%)
received medical 
treatment, n
Yes 65 (26.32%)
no 45 (18.22%)
Do not know/could not say 2 (0.01%)
Notes: asome men reported more than one occupation, therefore, percentages 
add to .100%; bbased on a bothersome rating scale of 0–10 (plus an ‘i don’t know’ 
option).
Abbreviations: iPss, international Prostate symptom score; sD, standard deviation.
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25.71% of men chose medication A, 32.75% chose medi-
cation B, and 41.54% chose no medication. Furthermore, 
12.55% of men always chose the “no medicine” alternative 
compared to 21.05% of men who always chose one of the 
medicines (either medicine A or medicine B).
The regression coefficients were statistically significant 
at a 5% level for day- and nighttime urinary frequency, 
two of three attribute levels for urinary urgency, all sexual 
side effects, two of three attribute levels for nonsexual side 
effects, and the cost of medication (Table 4). The positive 
coefficients indicate that men preferred reductions in the 
frequency of urination both during the day and at night, 
as well as reductions in urgency of urination from urge 
incontinence (base case) to moderate and mild urgency. The 
negative coefficients for sexual and nonsexual side effects 
and cost per month showed that, on average, men preferred 
medication without these attributes.
Three regression coefficients were not statistically signifi-
cant: men did not distinguish between urge incontinence and 
severe urgency, between taking one or two tablets per day, 
or viewed dry mouth as something to avoid. These results 
imply that, on average, these attributes did not influence 
men’s choice of medication.
There was a statistically significant preference variation 
in the population for several attributes (Table 4): reductions 
in day- or nighttime frequency; reductions in urinary urgency 
from urge incontinence to severe or moderate urgency; the 
sexual side effects of decreased sexual desire and erectile 
Table 3 Previous treatments for urinary symptoms (n=65)
Drug Frequency,a  
n
Relative  
frequency (%)
α1-blockers
Tamsulosin 29 44.6
Doxazosin 6 9.2
Alfuzosin 4 6.2
Terazosin 2 3.1
5α-reductase inhibitor
Finasteride 12 18.5
Dutasteride 2 3.1
Antimuscarinic
Oxybutinin 5 7.7
solifenacin 3 4.6
Tolterodine 2 3.1
Flavoxate 2 3.1
Darifenacin 1 1.5
Propiverine 1 1.5
combination therapy
Tamsulosin plus dutasteride 6 9.2
Note: aTen men had received two previous treatments.
Table 4 Mixed-logit regression coefficients, willingness-to-pay estimates, and standard deviations of significant coefficients
Attribute Regression 
coefficient (β)
P-value Standard 
deviation (σ)
P-value WTP 95% CI
constanta -0.377 0.212 2.771‡‡ ,0.001 ns ns
Daytime frequencyb 0.080‡‡ 0.002 0.114‡‡ ,0.001 £1.39 £0.55 to £2.23
nighttime frequencyb 0.384‡‡ 0.000 0.847‡‡ 0.001 £6.65 £4.36 to £8.94
Urinary urgencya
(Base case: urge incontinence)
severe urgency -0.164 0.376 1.255‡‡ ,0.001 ns ns
Moderate urgency 1.381‡‡ 0.000 0.863‡‡ ,0.001 £23.93 £17.36 to £30.51
Mild urgency 1.462‡‡ 0.000 0.518 0.054 £25.33 £19.00 to £31.67
sexual side effectsa
(Base case: no sexual side effects)
No fluid during ejaculation (dry orgasm) -0.969‡‡ 0.000 0.316 0.534 -£16.76 -£23.48 to -£10.11
Decreased sexual desire -1.135‡‡ 0.000 0.926‡‡ ,0.001 -£19.66 -£26.63 to -£12.68
erectile dysfunction -1.735‡‡ 0.000 0.035‡‡ ,0.001 -£30.07 -£38.01 to -£22.13
nonsexual side effectsa
(Base case: no nonsexual side effects)
Dry mouth -0.042 0.748 0.135 0.662 ns ns
headaches -0.939‡‡ 0.000 0.785‡‡ 0.002 -£16.26 -£22.00 to -£10.52
Dizziness -0.955‡‡ 0.000 0.666‡ 0.016 -£16.54 -£22.25 to -£10.83
number of tablets per day 0.083 0.425 Fixed coefficient ns ns
cost per month -0.058‡‡ 0.000 Fixed coefficient
log likelihood -1,862.062
Akaike information criterion 3,776.123
McFadden R2 0.21
Adjusted McFadden R2 0.20
n (observations) 7,410
Notes: ‡P,0.05; ‡‡P,0.01; acoefficient is normally distributed; bcoefficient is log-normally distributed.
Abbreviations: CI, confidence interval; NS, not significant; WTP, willingness to pay.
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dysfunction; and the nonsexual side effects of headache and 
dry mouth. However, there were no statistically significant 
variations in preference for an improvement from urge 
incontinence to mild urgency. This may reflect the variation 
in the sample about the degree of improvement represented 
by a move from urge incontinence to severe or moderate 
urgency, and the agreement in the sample about the benefit 
of the largest improvement from urge incontinence to mild 
urgency. The side effect of dry mouth also showed no sig-
nificant preference variation, implying this attribute was not 
important to men in our sample.
WTP
The value of reducing day- or nighttime frequency by one 
time was small compared to the value for a reduction of 
urgency and side effects (Table 4). In terms of symptom 
improvements, men were willing to pay more to reduce the 
frequency urination by one toilet visit at night compared with 
the day (£6.65/month vs £1.39/month). Men were willing 
to pay more to reduce urgency of urination than to reduce 
frequency of urination, for example, reducing urgency of 
urination from urge incontinence to mild urgency was valued 
at £25.33/month; this urinary urgency reduction is equivalent 
to reducing nighttime frequency by four urination events (ie, 
£25.33/£6.65). All sexual side effects reduced the value of 
medication; erectile dysfunction was considered to be the 
worst (£30.07/month). The other sexual side effects, no fluid 
during ejaculation (dry orgasm), and decreased sexual desire, 
had a similar impact on medication value as the nonsexual 
side effects of headaches and dizziness. Furthermore, the 
value of reduced urgency (to moderate or mild urgency) 
would compensate any one of the side effects, except for 
erectile dysfunction.
Discussion
This study estimated men’s preferences for medication 
attributes of treatments for LUTS/BPH. In terms of symp-
tom improvement, reducing urinary urgency was the most 
important benefit of medication, followed by a one-time 
reduction in night- and daytime urinary frequency. In terms of 
side effects, avoiding sexual and nonsexual side effects was 
also important to men; erectile dysfunction was perceived 
as the worst side effect. The results also showed preference 
variations in the importance of medication attributes for 
treatment choice in the sample.
Based on key findings from the earlier qualitative phase 
of this study, the DCE was designed to focus on the most 
bothersome symptoms (ie, storage symptom attributes 
of frequency and urgency) and men’s experience of their 
symptoms and treatment. As such, this DCE did not consider 
markers of treatment failure (eg, acute urinary retention or 
surgery) or treatment outcomes (eg, time to achieve improved 
symptoms or reduced prostate size), endpoints specifically 
associated with α
1
-blockers and 5-ARIs, which have been 
reported to be important to men with BPH40,41 and included 
in the previously published DCEs of BPH.21,35 The attribute 
levels for nonsexual side effects were expanded versus the 
previously published DCEs to include dry mouth, headache, 
and dizziness. Overall, these changes versus previous DCEs 
in BPH were designed to ensure our DCE focused on men’s 
experiences and make it more relevant to all currently rec-
ommended therapies.
Storage symptoms, which include urgency, increased 
daytime frequency, increased nighttime frequency, and urge 
incontinence, represent the most bothersome LUTS1,3,4 and 
are reported in 62% of men with LUTS.2 We found that the 
most valued attribute of medication was reduced urgency of 
urination from urge incontinence to moderate or mild levels. 
Men were willing to pay up to £24–25/month for the ability 
to postpone urination temporarily (moderate urgency) or as 
long as necessary, without fear of wetting themselves (mild 
urgency). In contrast, a change from urge incontinence to 
severe urgency (cannot postpone and have to rush to the 
toilet in order to not wet yourself) appeared to have little 
importance and men were not willing to pay for this level of 
change. Men also valued reductions in day- and nighttime 
frequency. These data are not unexpected given that storage 
symptoms are reported to impair quality of life42,43 and limit 
daily activities44 in men with LUTS.
The DCE showed that men prefer to avoid medications 
with sexual side effects and that erectile dysfunction has 
the strongest influence on choice, reducing the WTP by 
£30.07 per month. This is consistent with previous DCEs, 
which reported erectile dysfunction was the least desir-
able sexual side effect and confirmed the undesirability of 
decreased sexual desire and no fluid during ejaculation (dry 
orgasm).21,35 Our results suggest that restrictions on sexual 
activity, specifically described as an inability to be sexually 
active, have a large negative effect on men’s quality of life.
Men preferred treatments without headache and dizzi-
ness, which are reported nonsexual side effects of α
1
-blockers 
and phosphodiesterase type 5 inhibitors.33,45,46 In contrast, the 
prospect of dry mouth, associated with antimuscarinic use,33 
had a minimal impact on men’s preferences. This could be 
due to the fact that headache/migraine and dizziness are 
reported to impact work- and/or social-related activities.47,48 
It may also be because few men in our sample (n=14, 5.67%) 
had previously received antimuscarinic agents.
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Trade-offs are likely required when considering the effi-
cacy and side effect profiles of pharmacological treatment 
options available to men with LUTS/BPH. Considering the 
net benefit of a medicine for men based on the estimated 
WTP, a medicine targeting a mix of symptoms with a par-
ticular focus on reducing urgency of urination combined with 
reducing night-/daytime frequency is likely to provide the 
highest benefit for men. Such a combination of benefits may 
compensate for the negative impact of side effects. For exam-
ple, a therapy that reduced urgency to moderate urgency and 
provided one less nighttime urination (combined WTP esti-
mate, £30.58/month) has the potential to compensate for the 
side effect of erectile dysfunction (WTP estimate, -£30.07/
month). In contrast, the WTP estimates suggest that a therapy 
which only reduced nighttime frequency by one or two epi-
sodes per night (£6.65/month) would not compensate for 
decreased sexual desire (-£19.66/month).
A potential limitation of our study was that the DCE 
was limited to seven attributes that included urgency but 
excluded other LUTS symptoms (ie, voiding and/or post-
micturition) and other potential treatment-related factors as 
described earlier. However, increasing the number of attri-
butes increases the difficulty of completing the tasks,49,50 
meaning that respondents may provide less precise answers 
or may not consider all of the attributes.51,52 In addition, 
a greater number of attributes increases the number of 
choices needed to ensure the impact of each attribute can 
be identified in the statistical model. We consider that 
the selection of these seven attributes balances compre-
hensiveness of the symptoms and medication description 
and practicality of the survey administration. Another 
potential limitation of this DCE was that all surveys were 
completed online thereby excluding men without access 
to the Internet. However, the men were spread geographi-
cally across the UK limiting any potential regional bias 
and Internet usage in the UK is high, even in people aged 
$65 years.53 The results of this study are not generalizable 
beyond the UK.
Conclusion
In conclusion, treatment choice and the efficacy and toler-
ability profiles of medication are important factors for men 
with moderate-to-severe LUTS/BPH. Receiving medicines 
that significantly reduce storage symptoms, such as urge 
incontinence and nighttime urinary frequency, is perceived 
as the most important benefit of medication. However, men 
would prefer to avoid medicines that are likely to elicit sexual 
and nonsexual side effects. This study also highlights that 
treatment decisions may be optimized by understanding 
what symptoms and treatment benefits/side effects are of the 
greatest concern to patients with LUTS/BPH.
Acknowledgments
HERU is supported by the Chief Scientist Office at the 
Scottish Government Health and Social Care Directorate. 
Sebastian Heidenreich acknowledges financial support 
from the Institute of Applied Health Science, University of 
Aberdeen. Medical writing support was provided by Tyrone 
Daniel from Bioscript Medical and was funded by Astellas 
Pharma Europe Ltd. Presented in part as a poster at the 
ISPOR 17th Annual European Congress, November 8–12, 
2014, Amsterdam, the Netherlands. The poster’s abstract was 
published in Value in Health. 2014;17(7):A472.
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
DI, SH, MR, and VW are employed by the University of 
Aberdeen and performed the research which was funded by 
Astellas; CM, CN and JN are employees of Astellas. 
References
1. https://www.nice.org.uk/ [homepage on the internet]. London: National 
Institute for Health and Clinical Excellence (NICE); NICE clinical guide-
lines: CG97. Lower urinary tract symptoms: The management of lower 
urinary tract symptoms in men [updated 2010]. Available from: https://
www.nice.org.uk/guidance/cg97/evidence/full-guideline-245363870. 
Accessed August 19, 2015.
2. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding 
and postmicturition symptoms and implications for treatment seeking 
in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(Suppl 3): 
12–23.
3. Peters TJ, Donovan JL, Kay HE, et al. The International Continence 
Society “benign prostatic hyperplasia” study: the botherosomeness of 
urinary symptoms. J Urol. 1997;157(3):885–889.
4. Abrams P, Manson J, Kirby M. Incidence and epidemiology of storage 
lower urinary tract symptoms. Eur Urol Rev. 2012;7:50–54.
5. Gravas S, Bachmann A, Descazeaud A, et al. Guidelines on the manage-
ment of non-neurogenic male lower urinary tract symptoms (LUTS), incl. 
benign prostatic obstruction (BPO). European Association of Urology 
[guidelines on the internet]; 2015. Available from: http://uroweb.org/
wp-content/uploads/EAU-Guidelines-Non-Neurogenic-Male-LUTS-
Guidelines-2015-v2.pdf. Accessed August 19, 2015.
6. Auffenberg GB, Helfand BT, McVary KT. Established medical therapy 
for benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4): 
443–459, v–vi.
7. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 
2005;7(Suppl 9):S3–S14.
8. Chapple CR, Roehrborn CG. A shifted paradigm for the further under-
standing, evaluation, and treatment of lower urinary tract symptoms in 
men: focus on the bladder. Eur Urol. 2006;49(4):651–658.
9. Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract 
symptoms: evaluating the effect of LUTS on health-related quality of life, 
anxiety and depression: EpiLUTS. BJU Int. 2009;103(Suppl 3):4–11.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
09
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2415
Preferences for the treatment of lUTs associated with BPh
 10. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower uri-
nary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia 
(BPH) – focus on the UK. BJU Int. 2015;115(4):508–519.
 11. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and 
male sexual dysfunction: the multinational survey of the aging male 
(MSAM-7). Eur Urol. 2003;44(6):637–649.
 12. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. 
The impact of lower urinary tract symptoms on male sexual health: 
EpiLUTS. BJU Int. 2009;103(Suppl 3):33–41.
 13. Fourcade RO, Lacoin F, Roupret M, et al. Outcomes and general 
health-related quality of life among patients medically treated in general 
daily practice for lower urinary tract symptoms due to benign prostatic 
hyperplasia. World J Urol. 2012;30(3):419–426.
 14. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the 
treatment and follow-up of non-neurogenic male lower urinary tract 
symptoms including benign prostatic obstruction. Eur Urol. 2013; 
64(1):118–140.
 15. Aning JJ, Wassersug RJ, Goldenberg SL. Patient preference and 
the impact of decision-making aids on prostate cancer treatment 
choices and post-intervention regret. Curr Oncol. 2012;19(Suppl 3): 
S37–S44.
 16. Emberton M. Medical treatment of benign prostatic hyperplasia: physician 
and patient preferences and satisfaction. Int J Clin Pract. 2010;64(10): 
1425–1435.
 17. Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. 
Discrete choice experiments in health economics: a review of the 
literature. Pharmacoeconomics. 2014;32(9):883–902.
 18. http://www.fda.gov/ [homepage on the internet]. Maryland: Food 
and Drug Administration. Guidance for Industry and Food and 
Drug Administration Staff: Factors to Consider When Making 
Benefit-Risk Determinations in Medical Device Premarket 
Approval and De Novo Classifications [updated 2012 October 1]. 
Available from: http://www.fda.gov/downloads/MedicalDevices/
DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.
pdf. Accessed August 19, 2015.
 19. https://www.iqwig.de/ [homepage on the internet]. Köln: Institut für 
Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allge-
meine Methoden Version 4.1 [updated 2013]. Available from: https://
www.iqwig.de/download/IQWiG_General_Methods_Version_%20
4-1.pdf. Accessed August 19, 2015.
 20. http://www.ema.europa.eu/ema/ [homepage on the internet]. London: 
European Medicines Agency; Road map to 2015. The European Medi-
cine’s Agency Contribution to Science, Medicines and Health [updated 
2011]. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/Report/2011/01/WC500101373.pdf. Accessed 
August 19, 2015.
 21. Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. 
Eliciting preferences for drug treatment of lower urinary tract symp-
toms associated with benign prostatic hyperplasia. J Urol. 2004; 
172(6 Pt 1):2321–2325.
 22. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a 
trade-off technique to assess patients’ treatment preferences for benign 
prostatic hyperplasia. Med Decis Making. 1996;16(3):262–282.
 23. Swinburn P, Lloyd A, Ali S, Hashmi N, Newal D, Najib H. Prefer-
ences for antimuscarinic therapy for overactive bladder. BJU Int. 2011; 
108(6):868–873.
 24. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice 
experiments to elicit preferences. Qual Health Care. 2001;10(Suppl 1): 
i55–i60.
 25. Coast J, Al-Janabi H, Sutton EJ, et al. Using qualitative methods for 
attribute development for discrete choice experiments: issues and 
recommendations. Health Econ. 2012;21(6):730–741.
 26. Ritchie J, Lewis J, McNaughton Nicholls C, Ormston R, editors. 
Qualitative Research Practice. A Guide for Social Science Students 
and Researchers. London: SAGE Publications Ltd; 2014.
 27. Latini JM, Mueller E, Lux MM, Fitzgerald MP, Kreder KJ. Void-
ing frequency in a sample of asymptomatic American men. J Urol. 
2004;172(3):980–984.
 28. Fitzgerald MP, Brubaker L. Variability of 24-hour voiding diary variables 
among asymptomatic women. J Urol. 2003;169(1):207–209.
 29. Notte SM, Marshall TS, Lee M, et al. Content validity and test-retest 
reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) 
for overactive bladder. BMC Urol. 2012;12:26.
 30. Cartwright R, Panayi D, Cardozo L, Khullar V. Reliability and normal 
ranges for the Patient’s Perception of Intensity of Urgency Scale in 
asymptomatic women. BJU Int. 2010;105(6):832–836.
 31. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 
5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007; 
29(1):17–25.
 32. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)- 
adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3): 
287–301.
 33. Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. 
BMJ. 2014;349:g4474.
 34. Oefelein MG. Safety and tolerability profiles of anticholinergic agents 
used for the treatment of overactive bladder. Drug Saf. 2011;34(9): 
733–754.
 35. Eberth B, Watson V, Ryan M, Hughes J, Barnett G. Does one size fit all? 
Investigating heterogeneity in men’s preferences for benign prostatic 
hyperplasia treatment using mixed logit analysis. Med Decis Making. 
2009;29(6):707–715.
 36. Kuhfeld W. Marketing Research Methods in SAS: Experimental Design, 
Choice, Conjoint and Graphical Techniques. North Carolina: SAS 
Institute Inc; 2009.
 37. Horne R, Weinman J, Hankins M. The Beliefs about Medicines 
Questionnaire: The development and evaluation of a new method for 
assessing the cognitive representation of medication. Psychol Health. 
1999;14(1):1–24.
 38. Train K. Discrete Choice Methods with Simulation. New York: 
Cambridge University Press; 2002.
 39. Oehlert G. A note on the delta method. Am Stat. 1992;46(1):27–29.
 40. Emberton M, Marberger M, de la Rosette J. Understanding patient 
and physician perceptions of benign prostatic hyperplasia in Europe: 
The Prostate Research on Behaviour and Education (PROBE) Survey. 
Int J Clin Pract. 2008;62(1):18–26.
 41. Kaplan S, Naslund M. Public, patient, and professional attitudes towards 
the diagnosis and treatment of enlarged prostate: A landmark national 
US survey. Int J Clin Pract. 2006;60(10):1157–1165.
 42. Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J. Impact 
on quality of life of different lower urinary tract symptoms in men 
measured by means of the SF 36 questionnaire. Scand J Urol Nephrol. 
2006;40(6):485–494.
 43. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: 
fast control of the patient’s quality of life. Urology. 2003;62(3 Suppl 1): 
6–14.
 44. Tang DH, Colayco D, Piercy J, Patel V, Globe D, Chancellor MB. 
Impact of urinary incontinence on health-related quality of life, daily 
activities, and healthcare resource utilization in patients with neurogenic 
detrusor overactivity. BMC Neurol. 2014;14:74.
 45. Dolder CR. Dutasteride: a dual 5-alpha reductase inhibitor for the 
treatment of symptomatic benign prostatic hyperplasia. Ann Pharmaco-
ther. 2006;40(4):658–665.
 46. Dutkiewics S. Efficacy and tolerability of drugs for treatment of benign 
prostatic hyperplasia. Int Urol Nephrol. 2001;32(3):423–432.
 47. Mennini FS, Gitto L, Martelletti P. Improving care through health 
economics analyses: cost of illness and headache. J Headache Pain. 
2008;9(4):199–206.
 48. Bronstein AM, Golding JF, Gresty MA, et al. The social impact of 
dizziness in London and Siena. J Neurol. 2010;257(2):183–190.
 49. DeShazo J, Fermo G. Designing choice sets for stated preference 
methods: the effects of complexity on choice consistency. J Environ 
Econ Manage. 2002;44(1):123–143.
 50. Maddala T, Phillips KA, Reed Johnson F. An experiment on simplify-
ing conjoint analysis designs for measuring preferences. Health Econ. 
2003;12(12):1035–1047.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
09
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2416
Mankowski et al
 51. Viney R, Savage E, Louviere J. Empirical investigation of experimental 
design properties of discrete choice experiments in health care. Health 
Econ. 2005;14(4):349–362.
 52. Alemu M, Morkbak M, Olsen S, Jensen C. Attending to the reasons for 
attribute non-attendance in choice experiments. Environ Resour Econ. 
2013;54(3):333–359.
 53. https://www.ons.gov.uk/ [homepage on the internet]. London: Office 
for National Statistics. Internet Access Quarterly Update, Q1; 2014 
[updated 2014 May 14]. Available from: http://www.ons.gov.uk/ons/
dcp171778_362910.pdf. Accessed August 19, 2015.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
09
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2417
Preferences for the treatment of lUTs associated with BPh
Supplementary material
Description of mixed-logit model used 
to analyze discrete choice experiment 
responses
This approach allows preferences for attributes to vary across 
individuals and requires the specification of a distribution 
for each coefficient hypothesized to vary across participants. 
The distribution of the coefficients of the day- and nighttime 
frequency attributes was assumed to be log normal, given that 
all respondents ought to prefer reductions in the frequency 
of urination.1,2 All other coefficients were assumed to have a 
normal distribution, allowing for both positive and negative 
effects on utility. The estimation was based on 3,000 Halton 
draws using Stata version 13 (StataCorp LP, College Station, 
TX, USA).3 A fixed parameter was assumed for the cost 
attribute, thus assuming all individuals had the same negative 
preference, and allowing easier estimation of willingness to 
pay for all other attributes.4
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